关于我们
Calytrix Bio was founded in 2025 with a mission to transform the lives of patients living with myeloproliferative neoplasms (MPNs). Patients with these complex, progressive blood cancers have long hoped for truly disease-modifying therapies. At Calytrix Bio, we aspire to “change the course by going to the source.” We aim to deliver new therapeutic options, leveraging deep engagement with the MPN community and nimble development execution.
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Wellesley Hills，Massachusetts
- 类型
- 私人持股
- 创立
- 2025
Calytrix Bio员工
查看Calytrix Bio的 8 名员工
或
地点
-
主要
获取路线
20 William St
Suite 270
US，Massachusetts，Wellesley Hills，02481